---
title: "Citi: 2026 NRDL Negotiation Results Released; Drugmakers Say Price Cuts Mild and Manageable"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306083646.md"
description: "Citi reports that the 2026 NRDL negotiations are complete, adding 107 drugs and removing 34. Most pharmaceutical companies indicate price cuts were mild and manageable, despite significant reductions like JW Therapeutics' CAR-T product. The new list takes effect Jan 1, 2027."
datetime: "2026-11-19T08:06:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306083646.md)
  - [en](https://longbridge.com/en/news/306083646.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306083646.md)
generator: "portal-rs"
---

# Citi: 2026 NRDL Negotiation Results Released; Drugmakers Say Price Cuts Mild and Manageable

Citi released a research report saying that the National Healthcare Security Administration has completed negotiations for the 2026 National Reimbursement Drug List (NRDL). A total of 107 drugs were newly added to the list this year, including 51 innovative drugs from INNOVENT BIO (01801.HK) +2.000 (+2.395%) Short selling $142.34M; Ratio 37.175% , HUTCHMED (00013.HK) -0.220 (-1.014%) Short selling $6.34M; Ratio 18.586% , SKB BIO (06990.HK) -1.800 (-0.424%) Short selling $13.84M; Ratio 12.685% , 3SBIO (01530.HK) -0.150 (-1.128%) Short selling $20.08M; Ratio 33.051% , ASCENTAGE (06855.HK) -0.100 (-0.403%) Short selling $4.88M; Ratio 16.426% , JUNSHI BIO (01877.HK) +0.260 (+1.868%) Short selling $1.84M; Ratio 16.109% , EVEREST MED (01952.HK) -1.380 (-5.646%) Short selling $13.77M; Ratio 17.941% , CSPC PHARMA (01093.HK) +0.320 (+4.008%) Short selling $200.72M; Ratio 40.930% , HANSOH PHARMA (03692.HK) -0.260 (-0.795%) Short selling $55.09M; Ratio 47.494% , SBP GROUP (01177.HK) -0.050 (-0.923%) Short selling $28.43M; Ratio 32.872% , FOSUN PHARMA (02196.HK) -0.040 (-0.265%) Short selling $4.16M; Ratio 21.476% and CMS (00867.HK) -0.055 (-0.574%) Short selling $980.02K; Ratio 10.013% . Meanwhile, 34 drugs were removed from the list due to reasons including limited clinical value, availability of better alternatives, or insufficient necessary information in drug labels. The new list recorded a net increase of 78 drug specifications, bringing the total number of listed drugs to 3,331, including 1,935 western medicines and 1,396 traditional Chinese medicines.

Citi noted that JW THERAP-B (02126.HK) -0.220 (-9.283%) 's CAR-T product relma-cel entered the NRDL at a price of RMB288,600, representing a price cut of 77.6%. The innovative drug catalogue for commercial insurance newly included 12 drugs, including CAR-T therapies. Although post-negotiation drug prices for most products have yet to be disclosed, most pharmaceutical companies contacted by the bank guided that the price cuts were mild and manageable. The new catalogue will take effect from Jan 1, 2027, and the bank will monitor the final tender prices after implementation.(gc/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-19 12:25.)

### Related Stocks

- [HCM.US](https://longbridge.com/en/quote/HCM.US.md)
- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)
- [01177.HK](https://longbridge.com/en/quote/01177.HK.md)
- [00013.HK](https://longbridge.com/en/quote/00013.HK.md)
- [01530.HK](https://longbridge.com/en/quote/01530.HK.md)
- [01801.HK](https://longbridge.com/en/quote/01801.HK.md)
- [01877.HK](https://longbridge.com/en/quote/01877.HK.md)
- [01952.HK](https://longbridge.com/en/quote/01952.HK.md)
- [02126.HK](https://longbridge.com/en/quote/02126.HK.md)
- [02196.HK](https://longbridge.com/en/quote/02196.HK.md)
- [03692.HK](https://longbridge.com/en/quote/03692.HK.md)
- [06855.HK](https://longbridge.com/en/quote/06855.HK.md)
- [00867.HK](https://longbridge.com/en/quote/00867.HK.md)
- [600196.CN](https://longbridge.com/en/quote/600196.CN.md)
- [688180.CN](https://longbridge.com/en/quote/688180.CN.md)
- [06990.HK](https://longbridge.com/en/quote/06990.HK.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)

## Related News & Research

- [Fosun Pharma Starts Phase II Trial of FXR0906 for Hypertriglyceridemia in China](https://longbridge.com/en/news/305650774.md)
- [Hansoh Adds Three Innovative-Medicine Indications to 2026 NRDL](https://longbridge.com/en/news/305581132.md)
- [Everest Medicines Adds Two Drugs to China's Reimbursement List](https://longbridge.com/en/news/305665261.md)
- [Ascentage Pharma Group International Secures NRDL Coverage for Two Drugs](https://longbridge.com/en/news/305585817.md)
- [Innovent adds seven products to China’s 2026 NRDL](https://longbridge.com/en/news/305580225.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**